KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Debt to Equity (2020 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Debt to Equity for 9 consecutive years, with $0.03 as the latest value for Q1 2025.

  • On a quarterly basis, Debt to Equity fell 47.36% to $0.03 in Q1 2025 year-over-year; TTM through Mar 2025 was $0.03, a 47.36% decrease, with the full-year FY2024 number at $0.05, down 19.11% from a year prior.
  • Debt to Equity was $0.03 for Q1 2025 at Supernus Pharmaceuticals, down from $0.05 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.52 in Q4 2021 to a low of $0.02 in Q2 2023.
  • A 5-year average of $0.1 and a median of $0.05 in 2024 define the central range for Debt to Equity.
  • Biggest YoY gain for Debt to Equity was 1518.63% in 2022; the steepest drop was 95.42% in 2022.
  • Supernus Pharmaceuticals' Debt to Equity stood at $0.52 in 2021, then plummeted by 95.42% to $0.02 in 2022, then surged by 137.1% to $0.06 in 2023, then fell by 19.11% to $0.05 in 2024, then tumbled by 36.32% to $0.03 in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Debt to Equity are $0.03 (Q1 2025), $0.05 (Q4 2024), and $0.05 (Q2 2024).